Tianjin Lisheng Pharmaceutical Co.,Ltd.

002393.SZ

002393.SZTianjin Lisheng Pharmaceutical Co.,Ltd. CN flag

Shenzhen

16.67

CNY

-0.04

(-0.24%)

0.70EPS

23.81P/E

4.27BMarket Cap

May 16Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Tianjin Lisheng Pharmaceutical Co.,Ltd.

002393.SZ

(Shenzhen)

Recent

price

16.67

P/E

ratio

23.81

div

yld

5.62%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 05/14

Stock

S&P500

-11.56

12.14

12.18

46.67

-2.57

105.92

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
3.11	3.16	3.91	4.38	4.1	3.03	3.05	3.3	4.03	5.86	6.32	4.73	4.28	4.46	4.46	5.21	5.1	Revenue per Share
0.81	0.87	1.36	1.16	1.15	0.36	0.45	0.45	0.46	0.72	0.74	0.04	0.48	0.36	1.4	0.72	0.69	Basic EPS, GAAP
0.93	0.5	-0.1	0.1	-0.09	-0.86	-0.03	0.14	0.51	0.23	0.7	-0.1	0.42	1.13	0.54	0.13	-0.18	Free Cash Flow per Basic Share
0.25	0.65	0.65	0.62	0.64	0.44	0.23	0.3	0.23	0.22	0.22	0.23	0.07	0.21	0.21	0.47	0.44	Dividend per Share
0.93	1.75	2.67	3.09	3.56	3.45	3.66	3.75	3.97	4.4	4.85	4.92	5.02	5.1	6.11	6.7	6.74	Book Value per Share
1.92	10.92	11.91	10.47	11.04	10.97	11.27	11.32	11.44	17.16	16.65	17.22	16.72	16.4	18.49	17.73	17.42	Tangible Book Value per Share
191	233	255	255	255	255	254	257	256	256	256	241	255	257	258	256	263	Basic Weighted Avg Shares
596	738	998	1,117	1,044	774	775	847	1,029	1,504	1,615	1,141	1,092	1,147	1,153	1,336	1,341	Sales/Revenue/Turnover
35.56	32.92	25.85	28.81	29.19	11.41	16.58	13.61	9.55	11.43	12.13	5.09	4.18	7.28	11.44	6.75	6.5	Operating Margin (%)
17	17	25	25	24	26	25	49	56	55	61	63	60	66	67	81	- -	Depreciation Expense
155	203	346	297	293	93	114	116	117	185	188	9	122	94	362	185	181	Net Income, GAAP
17.52	17.28	13.36	16.89	15.83	17.12	15.64	13.26	10.71	13.56	13.22	72.15	10.95	20.92	13.89	13.89	14.58	Effective Tax Rate (%)
25.94	27.56	34.67	26.6	28.05	12	14.74	13.65	11.35	12.3	11.65	0.76	11.18	8.16	31.38	13.81	13.47	Profit Margin (%)
105	2,255	2,349	1,781	1,701	1,308	1,080	993	1,495	1,617	1,749	1,741	1,804	1,895	2,192	2,313	2,359	Working Capital
- -	- -	9	8	90	70	50	30	10	- -	- -	6	6	5	4	8	8	LT Debt
471	2,650	3,151	2,787	2,924	2,910	2,970	3,015	3,080	4,570	4,417	4,302	4,411	4,349	4,903	4,800	4,829	Total Equity
27.29	12.03	7.62	8.94	8.72	2.4	3.55	3.23	2.79	3.79	3.72	0.37	0.92	1.48	2.42	1.58	1.48	Return on Invested Capital (%)
34.36	43.86	58.78	38.78	31.61	9.29	11.46	11.31	11.11	16.17	15.28	0.71	9.68	7.06	24.43	10.87	9.84	Return on Capital (%)
75.44	69.41	63.66	40.51	34.59	10.39	12.63	12.22	11.81	17.25	15.87	0.71	9.89	7.23	25.05	11.2	10.59	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	7.23%	-2.44%	15.88%
Net Income, GAAP	152.14%	287.22%	-49%
Free Cash Flow	-97.13%	-123.47%	-75.04%
Total Cash Common Dividend	- -	- -	121.11%
Total Equity	5.99%	1.83%	-2.11%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: Levitee Labs Inc. (LVT.CN)
Baotou Dongbao Bio-Tech Co.,Ltd (300239.SZ)
Dakshidin Corporation, Inc. (DKSC)
Eris Lifesciences Limited (ERIS.NS)
Yuhan Corporation (000105.KS)
Labomar S.p.A. (LBM.MI)
Business: Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the production and sale of chemical medicines. The company offers tablets, hard capsules, dripping pills, freeze-dried powder injections, water injections, and bulk medicines, as well as intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. It also exports its products. The company is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.

	Sep'24	Dec'24	Mar'25
Total Current Assets	2,990	3,060	3,067
Accounts Receivable, Net	257	208	268
Cash, Cash Equivalents & STI	2,270	2,212	2,119
Inventories	227	224	223
Total Current Liabilities	746	747	708
Payables & Accruals	- -	- -	- -
ST Debt	83	43	32
Deferred Revenue	- -	- -	- -

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	TTM
3.11	3.16	3.91	4.38	4.1	3.03	3.05	3.3	4.03	5.86	6.32	4.73	4.28	4.46	4.46	5.21	5.1	Revenue per Share
0.81	0.87	1.36	1.16	1.15	0.36	0.45	0.45	0.46	0.72	0.74	0.04	0.48	0.36	1.4	0.72	0.69	Basic EPS, GAAP
0.93	0.5	-0.1	0.1	-0.09	-0.86	-0.03	0.14	0.51	0.23	0.7	-0.1	0.42	1.13	0.54	0.13	-0.18	Free Cash Flow per Basic Share
0.25	0.65	0.65	0.62	0.64	0.44	0.23	0.3	0.23	0.22	0.22	0.23	0.07	0.21	0.21	0.47	0.44	Dividend per Share
0.93	1.75	2.67	3.09	3.56	3.45	3.66	3.75	3.97	4.4	4.85	4.92	5.02	5.1	6.11	6.7	6.74	Book Value per Share
1.92	10.92	11.91	10.47	11.04	10.97	11.27	11.32	11.44	17.16	16.65	17.22	16.72	16.4	18.49	17.73	17.42	Tangible Book Value per Share
191	233	255	255	255	255	254	257	256	256	256	241	255	257	258	256	263	Basic Weighted Avg Shares
596	738	998	1,117	1,044	774	775	847	1,029	1,504	1,615	1,141	1,092	1,147	1,153	1,336	1,341	Sales/Revenue/Turnover
35.56	32.92	25.85	28.81	29.19	11.41	16.58	13.61	9.55	11.43	12.13	5.09	4.18	7.28	11.44	6.75	6.5	Operating Margin (%)
17	17	25	25	24	26	25	49	56	55	61	63	60	66	67	81	- -	Depreciation Expense
155	203	346	297	293	93	114	116	117	185	188	9	122	94	362	185	181	Net Income, GAAP
17.52	17.28	13.36	16.89	15.83	17.12	15.64	13.26	10.71	13.56	13.22	72.15	10.95	20.92	13.89	13.89	14.58	Effective Tax Rate (%)
25.94	27.56	34.67	26.6	28.05	12	14.74	13.65	11.35	12.3	11.65	0.76	11.18	8.16	31.38	13.81	13.47	Profit Margin (%)
105	2,255	2,349	1,781	1,701	1,308	1,080	993	1,495	1,617	1,749	1,741	1,804	1,895	2,192	2,313	2,359	Working Capital
- -	- -	9	8	90	70	50	30	10	- -	- -	6	6	5	4	8	8	LT Debt
471	2,650	3,151	2,787	2,924	2,910	2,970	3,015	3,080	4,570	4,417	4,302	4,411	4,349	4,903	4,800	4,829	Total Equity
27.29	12.03	7.62	8.94	8.72	2.4	3.55	3.23	2.79	3.79	3.72	0.37	0.92	1.48	2.42	1.58	1.48	Return on Invested Capital (%)
34.36	43.86	58.78	38.78	31.61	9.29	11.46	11.31	11.11	16.17	15.28	0.71	9.68	7.06	24.43	10.87	9.84	Return on Capital (%)
75.44	69.41	63.66	40.51	34.59	10.39	12.63	12.22	11.81	17.25	15.87	0.71	9.89	7.23	25.05	11.2	10.59	Return on Common Equity (%)

Year	Q1	Q2	Q3	Q4	FY
2023	336	322	254	241	1,153
2024	365	380	279	312	1,336
2025	370	- -	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	83	43	32
LT Borrowings	- -	- -	- -
LT Finance Leases	10	8	8
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	258	258	258
Market Capitalization	4,547	4,537	4,390

Year	Q1	Q2	Q3	Q4	FY
2023	0.18	- -	- -	- -	1.4
2024	0.23	- -	- -	- -	0.72
2025	0.21	- -	- -	- -	- -

Tianjin Lisheng Pharmaceutical Co.,Ltd.

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Working Capital

Quarterly Dividends Per Share

Year

Capital Structure

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year